India, Jan. 9 -- Aurobindo Pharma Ltd on Friday announced that its subsidiary, CuraTeQ Biologics Pvt Ltd, has received a Notice of Compliance (NOC) from Health Canada for its biosimilar Dyrupeg. The drug is indicated for cancer patients suffering from low neutrophil levels, a type of white blood cell.
The NOC was granted by the Biologics and Radiopharmaceutical Drugs Directorate following a successful review of Dyrupeg, which is a pegylated filgrastim biosimilar.
Aurobindo Pharma said in a regulatory filing that the approval confirms the product meets Health Canada's standards for safety, efficacy, and quality under applicable food and drug regulations.
Published by HT Digital Content Services with permission from Dion Global Solutions L...